معرفی
Associate Professor Alexander Menzies is a Medical Oncologist and holds academic positions at the Melanoma Institute Australia (MIA), The University of Sydney, and Royal North Shore and Mater Hospitals. He specializes in melanoma and breast cancer research, focusing on clinical trials of systemic therapies, biomarkers of treatment response, and immunotherapy-related toxicity. His roles include Chairing the Department of Cancer Medicine at the Mater Hospital, leading the Melanoma and Skin Group for the Clinical Oncology Society of Australia (COSA), and serving as Faculty member for European Society for Medical Oncology (ESMO).
- Education: BSc(Med), MBBS(Hons), FRACP, PhD
- Key affiliations:
- MelanoMA Institute Australia (MIA)
- University of Sydney's Northern Clinical School
- International Neoadjuvant Melanoma Consortium (INMC) founder
His research interests emphasize neoadjuvant systemic therapies, biomarker development for targeted and immune-based treatments, and immunotherapy-associated adverse events. Notably, his work explores how factors like ethnicity and tumor subtype influence outcomes of adjuvant anti-PD-1 therapy. He has pioneered collaborative networks between Australian, European, and U.S. melanoma centers to advance high-impact research.
Publications reflect a focus on melanoma and breast cancer clinical trials, immune response dynamics, and toxicity management. His articles highlight innovations in neoadjuvant regimens and biomarker-driven therapy selection, with contributions to journals like Nature, Lancet Oncology, and Journal of Clinical Oncology.
- Awards:
- NSW Premier's Award for Outstanding Cancer Research Fellow (2018)
Advising and grants: Supervises multiple PhD students and manages clinical/biospecimen databases at MIA. Leads over 100 sponsored/investigator-led trials since 2009. Collaborates internationally to optimize melanoma care through trials like the PRADO trial and INMC initiatives.
Labs/Teams: Active in the MIA, INMC, and Mater Hospital's Cancer Medicine Department. Co-leads the international neoadjuvant melanoma consortium and contributes to the Society for Melanoma Research Steering Committee.